🔥Trends in Cancer🆙 ✅Turning cold into hot: emerging strategies to fire up the tumor microenvironment 🎯Summary of the intrinsic, extrinsic, and systemic factors developing ‘cold’ tumors 👥Dr. Kaili Ma #LCSM OncoAlert #ICI cell.com/trends/cancer/…

Real-world outcomes of KRAS G12C & KRAS G12D+ NSCLC #LungCancer - 298pts (G12C=216; G12D=82)🇦🇺 - G12D ⬆️ in never smokers (15v1% p<0.01) &PDL1<1% (36v21% p=0.06) - No PFS/OS benefit from IO or chemoIO in G12D ⁦mayhemtom⁩ ⁦OncoAlert⁩ #LCSM sciencedirect.com/science/articl…

Happy to share our recent ESMO Open paper on the #safety and #feasibility of #outpatient administration of #tarlatamab as part of the #DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy. #LCSM 🫁 #SCLC Luis Paz-Ares Noemi Reguart

🚨 Can ctDNA Clearance Predict Response to Neoadjuvant Immunotherapy? 🧬🩸 Valenza et al., Annals of Oncology, 2025 📊 Systematic Review & Meta-analysis | 13 Trials | 380 Patients 🔍 Key Findings: ✅ Sensitivity of ctDNA clearance for predicting pathologic complete response

🫁 Stage III NSCLC 🫁 🫁 ASCO Guideline Rapid Recommendation Update Clinical Insights

Not all Lung adenocarcinomas (LUAD) respond the same. 📊Mucinous LUAD = 10% of cases, often KRAS+, TTF1–, PD-L1 low Worse outcomes across therapies: ICI ORR: 8.4% vs 25.9% IO+chemo OS: 11.4 vs 19.6 mo KRASG12C OS: 6.8 vs 10.8 mo Histology matters #LungCancer #NSCLC #KRAS

Impressive preliminary efficacy & safety of Zoldonrasib (RMC-9805) in KRAS G12D NSCLC 🔹MOA: oral RAS(ON) covalent, mutant-selective, G12D inhibitor 🔹 In 18 evaluable patients: ORR 61%, DCR 89% 🔹≥50% ctDNA clearance seen in majority of patients with detectable ctDNA at

🔑 #LungCancer #ClinicalTrials at #AACR25 ! Zongertinib in pretreated HER2 mut. NSCLC: Beamion LUNG-1 🔹ORR 71% (7% CR) with mDOR 14.1 mo 🔹mPFS 12.4 mo (95% CI, 8.2 to NR) 🔹Intracranial ORR 41% 🔹Pretx with HER2 ADC (cohort 5; n=31) ORR 48% 🔹Improved AE profile compared to

Dr. Shun Lu presents Phase 3 Aumolertinib (EGFR TKI) vs. Aumolertinib + platinum chemo in pts with EGFRmt stage 4 #lungcancer. - mPFS 28.9 combo vs. 18.9mo, HR 0.47 - with median f/u 24.4 mo, mOS not reached but data already favoring TKI:chemo arm with HR 0.44! AACR #AACR25

#ASCO25 Developmental Therapeutics CSS🔥 Another presentation on timing of chemo-IO, this time a large observational study of early (<11:30am) v late (>11:30am) IO: - early assoc with benefit in PFS & OS - OS HR 0.49 - pooled cohort of >700pts from 🇨🇳+🇫🇷 ASCO OncoAlert

💥 Landmark update by Sara Tolaney in HER2+ metastatic breast cancer at #ASCO25! 🎯 #destinybreast09 : T-DXd + pertuzumab combo 📈 PFS: 40.7 vs 26.9 mo 🧬 Benefit consistent across all subgroups ⚠️ But take note: 🔹 Grade ≥3 AEs: 54.9% 🔹 ILD: 12.1% (🕯️ 2 deaths) #BreastCancer

#ASCO2025 was filled with groundbreaking science. Feeling inspired and grateful to be part of this community. These are just a few of the top breast cancer studies presented, and some of the remaining questions.

Update from the Phase 2 PHAROS Study of encorafenib + binimetinib in #BRAF V600E NSCLC JTO & JTO CRR. As 1L therapy, RR 75%, DOR 40m, PFS 30m, 3y OS rate 53%. In previously treated, RR 46%, DOR 16.7m, PFS 9.3m, OS 22.7m, 3y OS 29%. jto.org/article/S1556-…

1/3 🫁 #Afatinib vs Chemotherapy with #Uncommon #EGFR Mutations: ACHILLES/TORG1834 ⭐️ Final OS analysis #ASCO25 Abstract #8623 #egfr #LCSM #uncommon #compound #afatinib

Early-stage lung cancer detection strategy! Dr.Logan Roof, MD, MS of The Ohio State University Wexner Medical Center details the Lung Nodule Clinic model—>60 lung cancers dx’d in Y1, 40+ early-stage cases received curative treatment; AI triage projected to 2× volume. MDT + centralized intake key. #DAVALung #LungCancer

“Old does not = frail.” Dr. Carolyn Presley Carolyn Presley, MD MHS discusses the design of the ACHIEVE study, emphasizing the inclusion of older adults, at DAVA Oncology #HawaiiLung25 #GeriOnc

You need some data as to how to use dato? Below guide offers a practical way to use Datroway in your clinic! ☑️mucositis ☑️pneumonitis ☑️ocular tox Now that Dato-dxd is approved for both breast and EGFR-mutated NSCLC indications, implementation of best practices is key! 👀

Thrilled to share our extensive work on LCNEC in collaboration with many centers and Caris Life Sciences now out in Nature Communications labour of love for 2+ years led by tireless efforts from Amin Nassar, MD and several others! nature.com/articles/s4146… Anne Chiang Chul Kim OU College of Medicine

⭐️I'm thrilled to share the results from EV-202, a multi-center Phase 2 trial of enfortumab vedotin (EV) in patients with advanced NSCLC - now in Eur J Cancer - EORTC! 👉🏾 ejcancer.com/article/S0959-… 👇🏾See below for highlights!🧵

🫁MTAP loss was present in 22.2% of #thymic carcinoma that underwent testing 🫁Dual loss of CDKN2A and CDKN2B was found in 30% of NGS tested samples 🫁More work to be done here but PRMT5 inhibitors may benefit these pts IASLC #WCLC25 ITMIG Society #thymsm #lcsm #lcam